ACTINIUM PHARMACEUTICALS, INC. Research and Development in Process
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Research and Development in Process of $2.71 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-31
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2020-03-31 was $1.50M, a 275.00% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2019-03-31 was $400.00K.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2014-09-30 was $300.00K.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2014-06-30 was $100.00K.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for fiscal 2022 was $2.71M, a 42.83% increase from fiscal 2021.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for fiscal 2021 was $1.90M.
- ACTINIUM PHARMACEUTICALS, INC. research and development in process for fiscal 2014 was $700.00K.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2022-12-31 | $2.71M 10-K · filed 2023-03-31 | ||
| 2021-12-31 | $1.90M 10-K · filed 2023-03-31 | ||
| 2020-03-31 | $1.50M 10-Q · filed 2020-06-29 | ||
| 2019-03-31 | $400.00K 10-Q · filed 2020-06-29 | ||
| 2014-12-31 | $700.00K 10-K · filed 2015-03-16 | ||
| 2014-09-30 | $300.00K 10-Q · filed 2014-10-31 | $400.00K derived: sum of 2 quarters · filed 2014-10-31 | |
| 2014-06-30 | $100.00K 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |